|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
1,770,000,000 |
Market
Cap: |
299.87(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$132.51 - $182.1 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 560 |
Guru Rank Value : 3 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile AbbVie is a research-based biopharmaceutical company. Co. operates as a single business segment dedicated to the research and development, manufacturing, commercialization and sale of medicines and therapies. Co.'s products include: immunology products such as Humira, Skyrizi, and Rinvoq; oncology products such as Imbruvica and Venclexta/Venclyxto; aesthetics products such as Botox Cosmetic and Juvederm Collection; neuroscience products such as Botox Therapeutic, Vraylar, and Ubrelvy; eyecare products such as Lumigan/Ganfort, Alphagan/Combigan, and Restasis; women's health products such as Lo Loestrin and Orilissa/Oriahnn; and other key products such as Creon, Lupron, and Synthroid.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
80,031 |
461,916 |
540,416 |
831,596 |
Total Sell Value |
$14,256,265 |
$81,646,316 |
$93,320,391 |
$138,453,569 |
Total People Sold |
2 |
9 |
9 |
12 |
Total Sell Transactions |
2 |
11 |
13 |
29 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Schumacher Laura J |
Vice Chairman |
|
2021-12-17 |
4 |
OE |
$54.86 |
$10,381,361 |
D/D |
181,670 |
394,673 |
|
- |
|
Stewart Jeffrey Ryan |
EVP, Chief Commercial Officer |
|
2021-12-15 |
4 |
S |
$128.00 |
$275,456 |
D/D |
(2,152) |
47,104 |
|
-21% |
|
Sorg Elaine K. |
SVP, US Commercial Operations |
|
2021-12-13 |
4 |
S |
$125.85 |
$812,739 |
D/D |
(6,458) |
0 |
|
-24% |
|
Sorg Elaine K. |
SVP, US Commercial Operations |
|
2021-12-10 |
4 |
D |
$124.15 |
$637,759 |
D/D |
(5,137) |
6,458 |
|
- |
|
Stewart Jeffrey Ryan |
EVP, Chief Commercial Officer |
|
2021-12-10 |
4 |
D |
$124.15 |
$212,669 |
D/D |
(1,713) |
49,256 |
|
- |
|
Gonzalez Richard A |
Chairman of the Board and CEO |
|
2021-12-09 |
4 |
S |
$122.80 |
$21,453,641 |
D/D |
(174,100) |
376,597 |
|
-28% |
|
Gonzalez Richard A |
Chairman of the Board and CEO |
|
2021-12-09 |
4 |
OE |
$61.36 |
$10,682,776 |
D/D |
174,100 |
550,697 |
|
- |
|
Richmond Timothy J. |
EVP, Chief HR Officer |
|
2021-12-06 |
4 |
S |
$120.00 |
$6,042,000 |
D/D |
(50,350) |
0 |
|
-31% |
|
Richmond Timothy J. |
EVP, Chief HR Officer |
|
2021-12-06 |
4 |
OE |
$58.88 |
$2,964,608 |
D/D |
50,350 |
50,350 |
|
- |
|
Austin Roxanne S |
Director |
|
2021-11-03 |
4 |
S |
$117.23 |
$2,344,600 |
D/D |
(20,000) |
49,284 |
|
-35% |
|
Austin Roxanne S |
Director |
|
2021-11-02 |
4 |
S |
$115.23 |
$6,033,384 |
D/D |
(51,844) |
69,284 |
|
-34% |
|
Gosebruch Henry O |
EVP, Chief Strategy Officer |
|
2021-09-07 |
4 |
GA |
$0.00 |
$0 |
I/I |
30,000 |
78,500 |
|
- |
|
Gosebruch Henry O |
EVP, Chief Strategy Officer |
|
2021-09-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
30,000 |
18,711 |
|
- |
|
Schumacher Laura J |
Vice Chairman |
|
2021-09-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,250 |
213,003 |
|
- |
|
Sorg Elaine K. |
SVP, US Commercial Operations |
|
2021-08-23 |
4 |
S |
$120.00 |
$1,569,600 |
D/D |
(13,080) |
11,595 |
|
-13% |
|
Sorg Elaine K. |
SVP, US Commercial Operations |
|
2021-08-23 |
4 |
OE |
$114.36 |
$809,669 |
D/D |
7,080 |
18,675 |
|
- |
|
Strom Carrie C |
SVP & Pres Global Allerg Aesth |
|
2021-08-23 |
4 |
S |
$120.00 |
$606,840 |
D/D |
(5,057) |
51,047 |
|
-13% |
|
Saleki-Gerhardt Azita |
EVP, Operations |
|
2021-05-24 |
4 |
S |
$116.24 |
$10,108,033 |
D/D |
(86,920) |
116,284 |
|
5% |
|
Saleki-Gerhardt Azita |
EVP, Operations |
|
2021-05-24 |
4 |
OE |
$29.23 |
$3,036,230 |
D/D |
86,920 |
203,204 |
|
- |
|
Strom Carrie C |
SVP & Pres Global Allerg Aesth |
|
2021-05-11 |
4 |
D |
$116.22 |
$335,527 |
D/D |
(2,887) |
56,104 |
|
- |
|
Alpern Robert J |
Director |
|
2021-05-07 |
4 |
A |
$115.96 |
$194,929 |
D/D |
1,681 |
30,121 |
|
- |
|
Hart Brett J |
Director |
|
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
14,076 |
|
- |
|
Meyer Melody B |
Director |
|
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
11,102 |
|
- |
|
Strom Carrie C |
SVP & Pres Global Allerg Aesth |
|
2021-05-07 |
4 |
D |
$116.08 |
$27,163 |
D/D |
(234) |
58,991 |
|
- |
|
Rapp Edward J |
Director |
|
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
27,163 |
|
- |
|
765 Records found
|
|
Page 9 of 31 |
|
|